Atossa Therapeutics, Inc. (NASDAQ: ATOS), a clinical stage biopharmaceutical company focused on developing innovative medicines to address unmet needs in oncology, particularly breast cancer, has announced its Board of Directors' approval of a share repurchase program. The program authorizes the repurchase of up to $10 million worth of the company's common stock, with the initiative set to continue until December 31, 2023.

‍

Atossa Therapeutics Launches $10 Million Stock Repurchase Program

Confidence in Long-Term Prospects:Dr. Steven Quay, President and CEO of Atossa Therapeutics, expressed the company's commitment to generating long-term value for its stockholders through strategic capital deployment. Recognizing the current macroeconomic environment and the bright future of Atossa, the share repurchase program is seen as a unique opportunity to drive stockholder value. Atossa focuses on breast cancer and ongoing Phase 2 studies for its (Z)-endoxifen development program.